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INTRODUCTION 
Cardiomyopathies are an important and heterogeneous group of 
diseases for which an understanding in both the public and medical 
community has historically been impaired by confusion surrounding 
definitions and nomenclature. Classification schemes, of which there 
have been many, are useful in defining and drawing relationships or 
distinctions between these complex diseases for the purpose of promoting 
greater clarity. 
Inadult population the prevalence of heart failure is estimated to be 
about 1 to 1.5%. The mortality and morbidity remain high (median 
survival of 3.2 years for women and 1.7 years for men).Up to 25% of all 
cases of CHF is caused byDilatedcardiomyopathy.The incidence and 
prevalence of CHF due to cardiomyopathy appears to be increasing. The 
incidence of DCM is reported to be 5 to 8 cases per 1,00,000 population 
per year. When compared to females DCM is 3 times more common in 
males. The frequency of occurrence is also more common in blacks1.  
Many classifications in the literature are to some degree 
contradictory in design, and indeed none of the proposed schemes can be 
regarded as ideal. The dilemma is caused by the heterogeneity in the 
presentation of this diverse group of diseases. A previous prominent 
classification of cardiomyopathies (1995) was represented in a very brief 
document under the auspices of the World Health Organization (WHO) 2. 
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 However, with the identification of new diseases over the past 
decade, and dramatic advances in cardiovascular diagnosis and 
knowledge regarding etiology, some disease definitions have become 
outdated and the WHO classification rendered essentially obsolete. 
Indeed, the past several years has witnessed a rapid evolution in the 
molecular genetics of cardiology. In particular, ion-channelopathies have 
emerged as conditions predisposing to potentially lethal ventricular 
tachyarrhythmias, caused by mutations in proteins leading to 
dysfunctional sodium, potassium, calcium, and other ion channels. 
Recently, under the auspices of the American Heart Association, a 
contemporary classification of cardiomyopathies has been presented, 
relying substantially on recent advances in the characterization of 
diseases affecting the myocardium. The new classification scheme 
affords a large measure of clarity to this area of investigation and 
facilitates interaction among the clinical and research communities in 
assessing the diagnosis, prognosis, and management of these complex 
diseases. 
The natural history of DCM remains incompletely understood. This 
is because this diagnosis clearly contains a variety of causes and patients 
have highly variable presentations. The presentations of patients can 
range from asymptomatic left ventricular dysfunction to mild, moderate, 
or severe congestive heart failure. Different studies report wide-ranging 
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estimates of annual mortality that are between 10% and 50%. 
Traditionally, it is held that symptomatic heart failure is invariably 
progressive. However, several factors suggest that this concept should be 
re-examined and that biologic factors may determine favourable or 
unfavourable long-term outcomes. 
The prognosis of DCM may be much more variable than 
previously appreciated.Several features of the clinical presentation may 
be valuable in predicting patient outcome 3. In addition, the underlying 
etiology of the cardiomyopathy clearly has a substantial impact on the 
natural history, thus warranting an exhaustive search for causes. Some 
cardiomyopathies have excellent long-term survival, whereas others, 
particularly amyloidosis and human immunodeficiency virus (HIV)–
related disease, carry grave prognoses. 
With theadvancement in molecular genetics and identification of 
underlying etiologies, dilated cardiomyopathy is being mentioned as a 
specific diagnosis and not by exclusion. The most common indication for 
cardiac transplantation in west is DCM.4,5 
In view of high prevalence of heart failure and also lack of data on 
dilated cardiomyopathy this study was undertaken. The ECG and 
echocardiography were also evaluated in the present study. 
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AIMS & OBJECTIVES 
 
Aim of the study is: 
1. To evaluate 100 cases of dilated cardiomyopathy and identify various 
etiology factors. 
2.To analyze the clinical profile of patients with dilated cardiomyopathy 
3.To study the electrocardiographic and echocardiographic profile of these 
patients 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 
 
REVIEW OF LITERATURE 
Historical aspects  
The term cardiomyopathy was first introduced in the year 1957 by 
Wallace Brigden of the National Heart Hospital, London to refer 
collectively a primary myocardial disease. Congenital, rheumatic, 
hypertensive or coronary artery disease were excludedby strict definition 
of myocardial hypertrophy, dilatation.To differentiate between ischemic 
and non-ischemic cardiomyopathies, Felker and associates used 
angiographic studies. 
In 1970 Burch and his associates used the term ischemic 
cardiomyopathy when they found that coronary artery disease can 
ultimately lead to myocardial dysfunction which is out of proportion to 
the level of ischemia or infarction. He also found that early 
revascularization can prevent the development of ischemic 
cardiomyopathy.  
The Framingham Heart Study showed that the heart failure is 
found to be twice in diabetic men and also five times more in diabetic 
women when compared with age-matched control subjects. This 
increased incidence of heart failure in diabetic patients persisted despite 
correction for age, obesity, hypercholesterolemia, hypertension and 
coronary artery disease. 
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  It was Rubler et al who first identified the existence of a diabetic 
cardiomyopathy in patients who had no evidence of coronary 
atherosclerosiswith congestive heartfailure. Chronic alcoholism can lead 
to cardiomyopathy, which was first described by Rubin et al. He also 
found that alcohol is toxic to cardiac muscle in a dose dependent manner. 
A syndrome of idiopathic heart failure in the early post partum 
period was first described by Ritchie et al. This was first described as 
post-partum cardiomyopathy and later replaced by peripartum 
cardiomyopathy. Majority of case presents during early post partum 
period but certain number cases can present even during last months of 
pregnancy. The criteria for diagnosis of peripartum cardiomyopathy were 
first described by Demakis et al. 
Echocardiographic and macroscopic features of dilated 
cardiomyopathy in HIV were first described in 1986 by Cohen and 
colleagues, which later came to be known as HIV cardiomyopathy.  
Cardiomyopathies were classified into  three categories namely 
congestive, hypertrophic and restrictive by Goodwin et al in 1970s .This 
classification is widely used and still valid in many circumstances. The 
term cardiomyopathy was to be used only for myocardial disease of 
unknown cause, proposed by WHO in 1980. In 1995, the WHO 
committee suggested a new classification system for dilated 
cardiomyopathy that includes a wide variety of myocardial diseases.  
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Recently, under the auspices of the American Heart Association 
(2006), a contemporary classification of cardiomyopathies has been 
presented,15 relying substantially on recent advances in the 
characterization of diseases affecting the myocardium.16-18 The new 
classification scheme affords a large measure of clarity to this area of 
investigation and facilitates interaction among the clinical and research 
communities in assessing the diagnosis, prognosis, and management of 
these complex diseases. This classification takes the place of the WHO 
document, but as new data emerge it also will undoubtedly require further 
review and revision. 
Definitions 
The proposed definition of cardiomyopathies is: A heterogeneous 
group of diseases of the myocardium associated with mechanical and/or 
electrical dysfunction, which usually (but not invariably) exhibit 
inappropriate ventricular hypertrophy or dilatation, and are due to a 
variety of etiologies that frequently are genetic. Cardiomyopathies are 
either confined to the heart or are part of generalized systemic disorders, 
often leading to cardiovascular death or progressive heart failure-related 
disability. 
Classification 
Most cases of heart failure are caused by heart muscle disease 
(cardiomyopathy). Within the classification of cardiomyopathies 6,7, the 
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most common cause of the clinical syndrome of heart failure is a 
secondary (ischemic, valvular, hypertensive, and so on ) or a primary 
(genetic, nongenetic, acquired) DCM, defined as a ventricular chamber 
exhibiting increased diastolic and systolic volumes and a low (<45%) 
ejection fraction 8. The natural history of the clinical syndrome of heart 
failure depends on the course of myocardial failure because (1) the most 
powerful single predictor of outcome is the degree of left ventricular 
(LV) dysfunction as assessed by the LV ejection fraction 9 (2) treatment 
that improves intrinsic ventricular function improves the natural history 
of heart failure; and (3) treatment that ultimately worsens intrinsic 
function, such as many types of positive inotropic agents, is associated 
with an adverse effect on outcome 10. 
The 1995 World Health Organization/International Society and 
Federation of Cardiology (WHO / ISFC) classification of 
cardiomyopathies7 was recently revised to accommodate several rapidly 
emerging realities, particularly the identification of new disease entities, 
advances in diagnosis, and knowledge of etiology of previously unknown 
types of heart muscle disease.6 
The new classification of cardiomyopathies is described in the 
WHO/ISFC classification of cardiomyopathy was mainly based on the 
global anatomic description of chamber dimensions in diastole and 
systole. Thus, therestrictive and dilated categories had definitions based 
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on left ventricular dimensions or volume, which also define function via 
calculated ejection fraction. The justification for this is that these two 
groups have distinct natural histories and respond differently to medical 
treatment. The novel AHA Scientific Statement emphasizes the genetic 
determinants of cardiomyopathies.  
Thus, dilated and restrictive cardiomyopathies are defined as mixed 
cardiomyopathies (predominantly nongenetic); however, hypertrophic 
cardiomyopathy (HCM), which is caused by mutations in contractile 
proteins, and other rare forms of cardiomyopathy, including 
arrhythmogenic right ventricular (RV) cardiomyopathy/dysplasia 
(ARVC/D) and LV noncompaction (LVNC), which also turned out to be 
completely genetic in basis, are defined genetic cardiomyopathies. The 
third category concerns acquired cardiomyopathies, such as peripartum 
and tachycardia-induced cardiomyopathies. Conversely, genetic 
cardiomyopathies without unique phenotypes and involvement of a 
generalized multiorgan disorder, such as the DCM of Becker-Duchenne, 
are defined as secondary cardiomyopathies. This distinction is arbitrary 
and may inevitably cause significant overlap between primary and 
secondary cardiomyopathies. 
Classification of the causes of cardiomyopathy continues to be a 
challenge, and a satisfactory and uniformly agreed on classification 
system remains in evolution11.Classification schemes are plagued by the 
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fact that as the causal basis of heart muscle disease becomes increasingly 
understood, it is also appreciated that for a given etiology, there may be a 
spectrum of phenotypes that can overlap or evolve. Recently, a new 
classification of cardiomyopathies that incorporates molecular insights 
was proposed by an American Heart Association Scientific Statement 
panel.11 
This classification divides cardiomyopathy into primary and 
secondary causes, in a manner similar to traditional classification 
schemes, but adds important sub characterization of the primary 
cardiomyopathies into genetic, mixed, and acquired groups. From the 
clinical perspective, where the objective is diagnosis and delivery of 
effective therapy that may be cause-specific, there is major overlap with 
the concept of an acquired primary cardiomyopathy and a secondary 
cardiomyopathy. An important new addition to the genetic subgroup is 
that of ion channel disorders, which often are not accompanied by 
structural heart disease but clearly can be considered a primary disorder 
of the heart. 
Based on all these considerations, the recommendation is that 
cardiomyopathies can be most effectively classified as 
Primary-genetic  
Primary-mixed (i.e., genetic and nongenetic)  
Primary-acquired  
Secondary 
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CLASSIFICATION OF CARDIOMYOPATHIES 
Dilated 
cardiomyopathy 
Dilation and impaired contraction of the left ventricle or 
both ventricles 
Caused by familial-genetic, viral, immune, alcoholic-
toxic, or unknown factors or is associated with 
recognized cardiovascular disease 
 
Hypertrophic 
cardiomyopathy 
Left and/or right ventricular hypertrophy, often 
asymmetric, which usually involves the 
interventricular septum 
Mutations in sarcoplasmic proteins cause the disease in 
many patients 
 
 
Restrictive 
cardiomyopathy 
Restricted filling and reduced diastolic size of either 
ventricle or both ventricles with normal or near-normal 
systolic function 
Idiopathic or associated with other disease (e.g., 
amyloidosis, endomyocardial disease) 
 
 
Arrhythmogenic 
right ventricular 
cardiomyopathy 
Progressive fibro fatty replacement of the right, and to 
some degree the left, ventricular myocardium 
Familial disease is common 
 
Unclassified 
cardiomyopathy 
Diseases that do not fit readily into any category; examples 
include systolic dysfunction with minimal dilation, 
mitochondrial disease, and fibroelastosis 
Specific Cardiomyopathies
Ischemic 
cardiomyopathy 
Arises as dilated cardiomyopathy with depressed 
ventricular function not explained by the extent of coronary 
artery obstructions or ischemic damage 
Valvular 
cardiomyopathy 
Arises as ventricular dysfunction that is out of proportion to 
the abnormal loading conditions produced by the valvular 
stenosis and/or regurgitation 
Hypertensive 
cardiomyopathy 
Arises with left ventricular hypertrophy with features of 
cardiac failure related to systolic or diastolic dysfunction 
Inflammatory 
cardiomyopathy Cardiac dysfunction as a consequence of myocarditis 
Metabolic 
cardiomyopathy 
Includes a wide variety of causes, including endocrine 
abnormalities, glycogen storage disease, deficiencies (such 
as hypokalemia), and nutritional disorders 
General systemic Includes connective tissue disorders and infiltrative diseases 
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disease such as sarcoidosis and leukemia 
Muscular 
dystrophies Includes Duchenne, Becker-type, and myotonic dystrophies
Neuromuscular 
disorders 
Includes Friedreich ataxia, Noonan syndrome, and 
lentiginosis 
Sensitivity and 
toxic reactions 
Includes reactions to alcohol, catecholamines, 
anthracyclines, irradiation, and others 
Peripartum 
cardiomyopathy 
First becomes manifested in the peripartum period, but it is 
probably a heterogeneous group 
PRIMARY CARDIOMYOPATHIES 
 
Source:AHA Scientific statement from the council on clinical cardiology, Circulation 
113:1807, 2006 
Dilated Cardiomyopathy 
The hallmarks of dilated cardiomyopathy (DCM), the most 
common cardiomyopathy, are enlargement of one or both of the 
ventricles and systolic dysfunction. It is not uncommon for chamber 
enlargement to precede signs and symptoms of congestive heart failure. 
Recent classification revision attempts recognize that chamber dilation is 
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part of the spectrum of genetic and environmental disorders affecting the 
heart; thus, a patient presenting with DCM may have a broad array of 
cardiac or systemic conditions. Nevertheless, DCM is an important and 
frequent clinical presentation. In 50% or more of patients with a DCM, an 
etiologic basis will not be identified, in which case the patient is referred 
to as having an idiopathic DCM.12,13 
Natural History 
The natural history of DCM remains incompletely understood. This 
is because this diagnosis clearly contains a variety of causes and patients 
have highly variable presentations. The presentations of patients can 
range from asymptomatic left ventricular dysfunction to mild, moderate, 
or severe congestive heart failure. Different studies report wide-ranging 
estimates of annual mortality that are between 10% and 50% 14. 
Traditionally, it is held that symptomatic heart failure is invariably 
progressive. However, several factors suggest that this concept should be 
re-examined and that biologic factors may determine favourable or 
unfavourable long-term outcomes.15 
 First, there has been an impact of therapy on the natural history of 
patients. Whereas the 1-year mortality in the placebo arm was 
approximately 50% in the Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS) conducted in the 1980s, similar patients 
experienced ~20% annual mortality in the Carvedilol Prospective 
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Randomized Cumulative Survival (COPERNICUS) trial conducted in the 
1990s, and this dropped further in the 2000s to ~10%. There is also 
growing awareness that treatment with pharmacologic therapies that 
antagonize the neurohormonal system can lead to myocardial recovery or 
“reverse left ventricular remodelling” in some patients with DCM. 
Finally, it is reported that between 25% and 33% of patients presenting 
with new-onset DCM experience meaningful cardiac recovery.16 
Prognosis 
The prognosis of DCM may be much more variable than 
previously appreciated.14,15Several features of the clinical presentation 
may be valuable in predicting patient outcome. In addition, the 
underlying etiology of the cardiomyopathy clearly has a substantial 
impact on the natural history, thus warranting an exhaustive search for 
causes. Some cardiomyopathies have excellent long-term survival, 
whereas others, particularly amyloidosis and human immunodeficiency 
virus (HIV)–related disease, carry grave prognoses.13 
A study using microarray analysis to measure gene expression in 
endomyocardial tissue obtained from patients suggested that patients who 
have favourable long-term outcomes accompanied by reverse 
remodelling can be detected at the time of clinical presentation.15 
Alternatively, it is clear that some patients may experience sudden 
deterioration after a period of stability or never experience a quiescent 
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time.17 It is also critical to appreciate that certain patients may have 
severe and life-threatening hemodynamic embarrassment at initial 
presentation. For these patients, a diagnostic evaluation including 
endomyocardial biopsy should be rapidly performed; these patients are 
critically ill and frequently require inotropic or mechanical support as a 
lifesaving therapy.18 
The determinants of the natural history are not entirely clear, but 
several studies suggest that biomarkers or panels of laboratory values 
may have prognostic value.14,15 
Pathology 
Macroscopic Examination 
Gross inspection of the heart demonstrates four-chamber 
enlargement. Most often, the ventricular walls are increased in thickness 
consistent with the myocyte hypertrophy that accompanies this disorder. 
Increasing chamber thickness is attributed to a compensatory mechanism 
aimed at reducing wall stress and is thus thought to play a beneficial role, 
averting further chamber remodeling.19 The valvular structures 
themselves are normal, although chamber enlargement frequently leads to 
a dilation of the valvular orifice. Intracavitary thrombi are often noted and 
are preferentially located in the ventricular apices. The coronary 
circulation is most commonly normal, although the presence of non-
occlusiveepicardial disease can raise a diagnostic conundrum wherein the 
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degree of cardiomyopathy is “out of proportion to the underlying 
coronary artery disease.”  
A definition for ischemic cardiomyopathy has been arbitrarily set 
at a requirement for a greater than 70% stenosis in a major epicardial 
coronary artery, although pathologic studies have reported greater 
degrees of disease.20 Preferential involvement of the right ventricle 
should suggest the diagnoses of arrhythmogenic right ventricular 
dysplasia/cardiomyopathy (ARVD/C) or corpulmonale (secondary to 
pulmonary hypertension). 
 
Histologic Examination 
Histologic evaluation of the myocardium reveals varying degrees 
of myocyte hypertrophy and interstitial fibrosis.20 Fibrosis most often 
affects the left ventricular sub endocardium or throughout the 
myocardium in interstitial or perivascular patterns. A finding of 
replacement fibrosis, an island of fibrotic tissue, often signifies a small 
area of tissue necrosis and suggests an ischemic etiology. It has been 
Gross Cardiac appearance showing four 
chamber enlargement 
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difficult to identify characteristic immunologic or infectious findings; 
however, progress is being made, particularly with regard to viral 
persistence within the heart. Scattered cells considered to be lymphocytes 
are a frequent observation and may lead to a diagnosis of borderline 
myocarditis. This does not appear to affect prognosis.21 
 
Cardiac myocytes hypertrophied   Interstitial deposits of fibrotic tissue 
Etiology 
DCM accounts for approximately 25% of the cases of congestive 
heart failure in the United States.22 The majority of the additional cases 
are due to specific cardiomyopathies, most notably ischemic or 
hypertensive cardiomyopathies, or nonsystolic heart failure.23 The DCM 
phenotype can be manifested from specific systemic diseases or primary 
acquired processes, and intensive diagnostic evaluations in referral 
centres can reveal a specific associated cause of cardiomyopathy in ~50% 
of patients; the remaining 50% are assigned the diagnosis of exclusion, 
idiopathic DCM.13 It is increasingly being appreciated that many of the 
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so-called cases of idiopathic DCM result from underlying genetic 
abnormalities or previous environmental insults that are difficult to detect 
at the time of clinical presentation. With the advent of sophisticated 
molecular and imaging technologies in clinical medicine, it is likely in the 
future that an increasing number of the idiopathic cases will have a 
specific diagnosis assigned. 
Specific Cardiomyopathies with a Dilated Phenotype 
Clinically, there are a host of important causes of secondary DCM 
that include alcohol and cocaine abuse,HIV infection,and metabolic 
abnormalities as well as the cardio toxicity of anticancer drugs,most 
notably doxorubicin and newly introduced drugs that inhibit tyrosine 
kinases (e.g., Herceptin and imitinab). The following four specific 
disorders are particularly important to recognize in that correct diagnosis 
has a major impact on patient management and chance for recovery. 
Stress (Tako-tsubo or Broken Heart Syndrome) 
An acute cardiomyopathy can be provoked by a stressful or 
emotional situation or exposure to high doses of catecholamines 
(sympathomimetic drugs).24,25This cardiomyopathy is most common 
among middle-aged women, appears to be related to catecholamine 
release, and in most cases is fully reversible with supportive care. 
Electrocardiographic findings of myocardial infarction in the presence of 
left ventricular dysfunction and absence of epicardial coronary stenosis 
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should prompt the diagnosis. Endomyocardial biopsy is of value to 
exclude myocarditis, which can also mimic acute myocardial infarction, 
and demonstrates contraction band necrosis. 
Peripartum Cardiomyopathy 
Peripartum cardiomyopathy26,27is defined as a cardiomyopathy 
manifesting between the last month of pregnancy and 6 months post 
partum. The etiology is unclear, but inflammatory factors are highly 
implicated, and some studies reveal a high incidence of lymphocytic 
inflammation. Peripartum cardiomyopathy is common in Africa but also 
is manifested in the developed world; it has an excellent long-term 
natural history if patients survive the initial period, during which time 
hemodynamic compromise may be severe28. Prognosis is worse in the 
developing world and among indigent patients in the United States29.  
It is important to differentiate peripartum cardiomyopathy from a 
chronic cardiomyopathy exacerbated by the volume load occurring during 
pregnancy26. Women who recover are at increased risk of recurrences 
with subsequent pregnancies; women with full recovery are more likely 
to tolerate a subsequent pregnancy than are those with. Peripartum 
cardiomyopathy leads to left ventricular systolic dysfunction are a form 
of DCM that results in signs and symptoms of heart failure. The criteria 
used for diagnosis of peripartum cardiomyopathy are as follows: 
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1. The development of heart failure in the last month of pregnancy or 
within 5 months of delivery 
2.  Absence of an identifiable etiology for the heart failure, 
3.  Absence of identifiable cardiac disease prior to the last month of 
pregnancy 
4.  Echocardiography demonstrates left ventricular systolic 
dysfunction. 
Tachycardia-Induced Cardiomyopathy 
Patients may develop a DCM with congestive heart failure in the 
face of recurrent or persistent tachycardias. The most common 
association is with atrial fibrillation or supraventricular tachycardia. 
There is a high rate of full recovery with control of the arrhythmia30. This 
cardiomyopathy is notable for the degree to which it resembles idiopathic 
DCM phenotypically, yet it is characterized by a remarkable degree of 
recovery in left ventricular function once the arrhythmia is controlled. 
Patients presenting with an atrial or supraventricular arrhythmia should 
undergo definitive therapy to control heart rate and to restore normal 
sinus rhythm.  
Alcoholic Cardiomyopathy 
For more than hundred years the toxic effects of alcohol have been 
known. Initially it was thought that the manifestations were due to 
nutritional deficiency rather than direct alcohol effects. Also additives in 
alcohol were found to be the cause of heart dysfunction in chronic 
alcoholics. The direct effects of alcohol leading to cardiomyopathy and 
also skeletal abnormalities were first described by Rubin et al. He 
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demonstrated that in a dose dependent manner alcohol is toxic to cardiac 
and striated muscle.31,32 
An alcohol cardiomyopathy is diagnosed only when other causes 
of a dilated cardiomyopathy have been ruled out and there is a history of 
heavy and sustained alcohol intake. The dose requires to cause alcoholic 
cardiomyopathy is around 100g for several years. In susceptible 
individuals it is likely that even lower amounts of alcohol intake can 
produce cardiomyopathy. The histologic findings of alcohol 
cardiomyopathy are found to be nonspecific and that do not differ from 
idiopathic dilated cardiomyopathy. Other than history and examination 
the only probable distinguishing feature between idiopathic dilated 
cardiomyopathy and alcohol cardiomyopathy is that alcohol 
cardiomyopathy may present with a features of high cardiac output 
failure31. 
Diabetic cardiomyopathy 
The Framingham Heart Study found that the frequency of cardiac 
failure is twice in diabetic men and five times more in diabetic women 
compared with age-matched control groups. Even after correction of 
hypertension, obesity, hypercholesterolemia, and coronary artery disease 
the diabetic cardiomyopathy still persists. The existence of diabetic 
cardiomyopathy in the presence of normal coronary arteries was first 
described by Rubler et al. Epidemiologic evidence of an association of a 
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specific DCM with diabetes became evident with the Framingham 
study33,34.  
The characteristic histopathological findings are fibrosis, which 
may beinterstitial, perivascular, or both. As the pathology progresses, 
there is increased myocyte loss and with replacement fibrosis. Common 
histopathologic findings of diabetic cardiomyopathy include small vessel 
disease, myocardial hypertrophy and interstitial fibrosis. The clinical 
features include symptoms and signs of heart failure in a patient with long 
standing diabetes mellitus. Diastolic dysfunction may be evidenteven 
much before systolic function is impaired. Management consists of 
treatment of congestive heart failure and glycaemic control. 
Miscellaneous cardiomyopathies 
HIV cardiomyopathy 
The clinical, echocardiographic and also macroscopic findings of dilated 
cardiomyopathy in patients with HIV35was first described by Cohen and 
Colleagues. The mechanisms leading to dilated cardiomyopathy in HIV 
include 
1.  Post viral myocarditis: HIV itself can lead to cardiac dilatation and 
dysfunction. Viral infection causes an immune reaction to viral 
antigen that cross react with myocardial protein. Anti-myosin 
antibodies have been demonstrated in patients with HIV and 
cardiomyopathy. HIV infected monocytes may produce cytokines 
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which damages the cardiacmyocytes (innocent bystander 
mechanism) 
2.  Drug induced cardiomyopathy:Interferons,zidovudineetc can lead 
to cardiomyopathy. 
3.  Selenium andvitamin deficiency have also been implicated. 
4.  HIV patientswith concomitant cocaine abuse can also lead to 
dilated cardiomyopathy. 
5.  Other opportunistic infections liketoxoplasma,mycobacterium 
aviumintracellulare,cryptococcus,etc can also lead to 
cardiomyopathy. In advanced case of HIV cardiomyopathy is seen 
and in most patients biventricular failure is seen. For HIV 
cardiomyopathythere is no specific treatment. 
Etiologic Basis for Idiopathic Dilated Cardiomyopathy  
Rapidly advancing knowledge in four areas is shedding light on 
pathophysiologic mechanisms that may contribute to DCM and may in 
turn lead to new therapeutic approaches. These areas include (1) familial 
and genetic factors36, (2) inflammatory and infectious factors, particularly 
viral infection37, (3) cytotoxicity, and (4) cell loss and abnormalities in 
endogenous repair mechanisms38,39. 
Genetic and Familial Factors 
Studies of the genetics of DCM offer major insights into the 
etiology of the disease. Two general lines of evidence initially suggested 
a genetic component to DCM. Familial studies indicated that in excess of 
20% of patients with DCM had other family members with the condition, 
and conversely, certain inherited conditions, particularly muscular 
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dystrophies, had cardiomyopathy as a component. There are now 
abundant gene linkage studies with multiple genes identified; autosomal 
dominant and recessive as well as X-linked modes of inheritance exist36. 
A mutation in the gene encoding phospholamban implicates 
abnormalities in the excitation-contraction cascade as a cause of 
cardiomyopathy and supports attempts to treat cardiomyopathy with other 
elements of the calcium cycling machinery (i.e., delivery of the gene 
encoding the sarcoplasmic reticulum calcium pump [SERCA])40. 
The fact that genetic abnormalities play a role offers insights into 
the phenotype in general. Clearly, genetic predisposition may be a central 
factor in the development of primary and secondary DCMs. Genetic 
defects may be primary causes of DCM, or they may act as predisposing 
factors in the setting of an environmental stressor-host-environment 
interaction. Primary examples of the latter are viral infections and 
hypertension, wherein exposure may lead to DCM only in subpopulations 
of exposed individuals. Genetic predisposition may be of fundamental 
importance in the variable natural history of DCM and may contribute to 
responsiveness to therapy41. 
Knowledge of the genetics of DCM has led to the entry of genetic 
screening into the clinical arena and the development of specialty clinics 
at referral centres. Recent guidelines suggest that genetic screening and 
counselling should be considered in families in whom familial DCM is 
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suspected, as a means of early detection of cardiomyopathy in family 
members36. 
Inflammatory and Infectious Myocarditis 
Myocarditis may result from viral (or other pathogen) infection, 
autoimmune disease, or a combination (autoimmune reaction stimulated 
by a viral infection)42. It is also increasingly possible that genetic factors 
increase the risk for development of cardiac disease after viral infection. 
It has long been postulated that viral infection in susceptible hosts 
may be a proximate cause of cardiomyopathy and may serve as a 
precursor to the development of DCM. This hypothesis has been difficult 
to prove because of challenges in confirming viral infection in affected 
individuals coupled with the fact that common viruses are implicated in 
viral cardiomyopathy, leading to concerns of a high false-positive rate 
when viruses are detected in patients with heart failure. Lymphocytic 
myocarditis with or without myocyte necrosis has been considered the 
hallmark diagnostic finding necessary for a diagnosis, and criteria 
established for the histologic evaluation are termed the Dallas criteria42.  
Two general mechanisms for postviral cardiac injury have been 
invoked: autoimmune reactions and direct tissue injury resulting from 
viral infection of the heart. Both of these mechanisms are incompletely 
proved and remain controversial. The presence or absence of 
inflammation on endomyocardial biopsy, which varies greatly from study 
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to study, is used to substantiate immunologic injury. However, other 
studies have suggested different criteria (e.g., complement or 
immunoglobulin deposition). The postviral hypothesis has increasing 
support, and viral material has been detected on the basis of elevated viral 
titers, presence of viral genomic material by PCR, and detection of viral 
particles. 
Autoimmunity 
Studies support abnormalities of humoral and cellular immunity in 
DCM. Two general theories are proposed for an autoimmune cause of 
DCM: (1) viral components incorporate into the cardiac myocyte 
membrane, stimulating an antigenic response; and (2) anti–heart 
antibodies are generated as a result of myocardial damage as opposed to 
being the proximate cause. Certain specific human leukocyte antigen 
(HLA) class II antigens (particularly DR4) are associated with DCM. In 
addition, numerous circulating antimyocardial antibodies have been 
measured in DCM patients that react with a variety of antigens, including 
the myosin heavy chain, the beta adrenoceptor, the muscarinic receptor, 
sarcolemmal sodium-potassium adenosine triphosphatase, laminin, and 
mitochondrial proteins. A regimen of prednisone and azathioprine has 
recently been shown to improve ejection fraction in patients with virus-
negative myocarditis43. 
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Cytotoxicity and Deranged Intracellular Signalling 
The direct action of various circulating factors is implicated in the 
pathophysiology of myocyte dysfunction. For example, tumor necrosis 
factor and endothelin levels are elevated in DCM. The exact role of these 
factors remains incompletely understood, and therapies to antagonize 
their effects have not been definitively established. 
An additional molecular mechanism gaining increased 
experimental and clinical support is that of nitroso-redox imbalance, an 
intracellular phenomenon characterized by dysregulation of nitric oxide 
production coupled with increased production of reactive oxygen 
species44.This imbalance is described in experimental animal models and 
in humans with DCM and causes cellular dysfunction and possibly 
cytotoxicity. Although not definitively proved, one mechanism postulated 
to explain the response of DCM patients to hydralazine–
isosorbidedinitrate is a restoration of nitroso-redox balance. 
Injury, Cell Loss, and Endogenous Repair 
A variety of other causes related to damage to cellular constituents 
of the heart are proposed as etiologic factors. Although none is accepted 
as the absolute cause, the variety of mechanisms highlights the notion of 
a final common pathway, with various insults converging on a set of 
mechanisms that all result in a common phenotypic response to injury. 
Many of the mechanisms, such as endocrine disturbances and toxic 
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exposures, derive from the existence of specific examples of secondary 
cardiomyopathies.  
Ischemia due to hyperreactivity or spasm of the microvasculature 
may contribute to diffuse myocyte necrosis and replacement fibrosis. The 
classic disorder in which this is manifested is scleroderma heart disease. 
Increased myocyte apoptosis is described in DCM and ARVD/C, leading 
to the suggestion that augmented cell loss may contribute to the 
development of left ventricular remodeling in DCM processes. Although 
there are an increasing number of experimental studies supporting cardiac 
recovery when antiapoptotic agents are administered in animal models45, 
the exact role of apoptosis in these conditions is not known. Further, the 
role of cell loss in DCM has become more interesting in light of recent 
accumulating data supporting the idea that endogenous cardiac stem cells 
repopulate cardiac myocytes throughout life39, thereby serving a 
homeostatic balancing mechanism for ongoing cell loss and cell 
replacement after tissue injury. Indeed, studies already support the idea of 
cardiac stem cell senescence contributing to the development of human 
cardiomyopathy38. Thus, depletion or dysfunction of endogenous cells 
with capacity to divide and to differentiate in cardiac cellular constituents 
may be a central pathophysiologic contributor to cardiomyopathic 
processes. 
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Clinical Evaluation of the Dilated Cardiomyopathies  
History 
DCM affects individuals of all ages, including neonates and 
children46,47. In adults, the incidence of DCM is estimated to be between 5 
and 8 per 100,000 persons per year. DCM is most frequent in middle age 
and affects men to a greater degree than women. Although the incidence 
of ischemic cardiomyopathy is higher than that of DCM, these two 
diagnoses account for an equal number of heart transplantations 
performed. 
In the case of DCM, the clinical presentation of patients can vary 
substantially. In some patients, symptoms develop very gradually and 
diagnosis can result from the detection of cardiomegaly on routine chest 
radiography. Intercurrent illnesses frequently precipitate congestive heart 
failure in individuals with DCM. A significant minority of patients with 
DCM present with aggressive, life-threatening congestive heart failure 
(fulminant heart failure) that can require the most intensive forms of 
mechanical intervention21. The causes of the fulminant presentation vary 
from idiopathic cardiomyopathy to fulminant lymphocytic myocarditis to 
giant cell myocarditis18,22. The determinants of these various forms of 
clinical presentation are poorly understood. 
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Evaluation for Secondary Cardiomyopathies  
An initial history must focus on identifying etiologic factors13. A 
past or associated history of rheumatologic, endocrine, or infectious 
diseases or of previous neoplasia should be sought.In patients with a 
history of cancer, treatment with anthracyclines, tyrosine kinase 
inhibitors, or irradiation is particularly relevant. The family history can 
often reveal heritable forms of cardiomyopathy. Patients should be 
questioned about the consumption of alcohol, tobacco, and illicit drugs. 
Travel history can reveal exposure to geographically related infectious 
pathogens. 
The most typical symptoms are those of congestive heart failure 
and include dyspnoea, fatigue, and volume gain. A minority of patients 
report chest pain, which can signify epicardialcoronary disease, 
subendocardial disease, or pulmonary embolism. A report of abdominal 
discomfort or anorexia is frequent in late stages of the disease and 
suggests hepatomegaly or bowel edema, respectively. 
Common late complications include thromboembolic events, which 
may be systemic, originating from dislodgment of left atrial and 
ventricular intracardiac or pulmonary thrombi from the lower extremity 
venous system. 
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Physical Examination 
Particular attention should be paid in the physical examination to 
excluding findings of valvular heart disease. S3 and S4 gallops are 
invariably present in DCM. The S3 must be differentiated from a 
pericardial knock or an opening snap of mitral stenosis, both of which are 
higher pitched sounds than the S3. Patients with fulminant heart failure of 
new onset will frequently be tachycardic and will develop a gallop 
rhythm in which S3 and S4 fuse. Attention should be paid to 
differentiation of right-sided gallops and murmurs to consider the 
possibility of right-sided involvement. 
NEWYORK HEART ASSOCIATION CLASSIFICATION 
Functional   
Capacity 
Objective Assessment 
Class I Patients with cardiac disease but without resulting 
limitation of physical activity. Ordinary physical activity 
does not cause undue fatigue, palpitations, dyspnoea, or 
anginal pain. 
Class II Patients with cardiac disease resulting in slight 
limitation of physical activity. They are comfortable at 
rest. Ordinary physical activity results in fatigue, 
palpitation, dyspnoea, or anginal pain. 
Class III Patients with cardiac disease resulting in marked 
limitation of physical activity. They are comfortable at 
rest. Less than ordinary activity causes fatigue, 
palpitation, dyspnoea, or anginal pain. 
Class IV Patients with cardiac disease resulting in inability to 
carry on any physical activity without discomfort. 
Symptoms of heart failure or the anginal syndrome may 
be present even at rest. If any physical activity is 
undertaken, discomfort is increased. 
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American College of Cardiology/American Heart Association Stages 
of Heart Failure 
 
Stage Definition Patient Description 
A High risk for developing 
heart failure (HF) 
Hypertension 
Coronary artery disease 
Diabetes mellitus 
Family history of cardiomyopathy 
B Asymptomatic HF Previous myocardial infarction (MI) 
LV hypertrophy or systolic dysfunction 
Asymptomatic valvular disease 
Known structural heart disease 
C Symptomatic HF Shortness of breath and fatigue 
Reduced exercise tolerance 
D Refractory end-stage HF Marked symptoms at rest despite maximal 
medical therapy (e.g., those who are 
recurrently hospitalized or cannot be 
safely discharged from the hospital 
without specialized interventions 
Non-invasive Evaluation 
For patients presenting with DCM, the initial evaluation should 
focus on identification of reversible and secondary causes. Even though 
the presentation of the patient with a dilated ventricle and heart failure 
may be fairly uniform, a wide array of specific and secondary 
cardiomyopathies may cause a clinical presentation of a DCM. The first 
step in the diagnostic evaluation involves screening biochemical testing, 
including serum electrolytes, phosphorus, calcium, and markers of renal 
function (serum creatinine and urea) 13. Endocrine function should be 
screened, notably thyroid function (hyperthyroidism and hypothyroidism) 
and possibly urinary evaluation of catecholamine levels to exclude 
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pheochromocytoma. To screen for rheumatologic conditions, an 
antinuclear antibody and erythrocyte sedimentation rate should be 
obtained. When suspected, rarer causes of cardiomyopathy can be 
excluded with blood testing. For example, Lyme titres can be a useful 
screen for Lyme carditis. Iron studies may assist in evaluating 
hemochromatosis, and HIV testing is valuable. 
The use of biomarkers (such as troponin) to assess myocardial 
necrosis and the use of circulating brain natriuretic peptide (BNP or pro-
BNP) levels may serve as useful adjunctive strategies to help determine 
diagnosis or prognosis. Further, there is increasing support for the use of 
serum uric acid levels as a prognostic marker14,48. A chest radiograph 
offers supporting evidence for the diagnosis and in some cases is the 
initial mode of detection. Cardiomegaly may be appreciated, as may 
evidence of pulmonary vascular redistribution. Rarely, interstitial and 
alveolar oedema is present on initial presentation. With advancing heart 
failure, pleural effusions are present, and dilated azygos veins and 
superior vena cava indicate right-sided volume overload. 
Electrocardiography 
There are no specific electrocardiographic findings signifying 
DCM. Sinus tachycardia is often present in proportion to the degree of 
heart failure. Typical changes in the QRS complex include poor R wave 
progression, intraventricular conduction delays, and left bundle branch 
34 
 
block. A wide QRS complex portends a worse prognosis and has now 
emerged as a clinical indicator of responsiveness to cardiac 
resynchronization therapy. Patients with substantial left ventricular 
fibrosis may exhibit anterior Q waves even in the absence of a discrete 
scar or epicardial coronary artery obstructions.  
A broad array of abnormalities may be manifested, such as 
nonspecific ST-segment and T wave abnormalities as well as P wave 
alterations, notably left atrial abnormality. Nonsustained ventricular 
tachycardia is extremely common on 24-hour ambulatory monitoring and 
represents a predictor of all-cause mortality. Persistent supraventricular or 
ventricular tachyarrhythmia’s represent an important etiologic factor for 
ventricular dysfunction, 30 and restoration of sinus rhythm or heart rate 
control may lead to recovery of ventricular function. Control of atrial 
fibrillation is also important because of atrial transport issues contributing 
to cardiac output. In addition, atrial fibrillation should prompt 
consideration of tachycardia-induced cardiomyopathy. 
Echocardiography 
Echocardiography is a cornerstone in the evaluation and 
management of patients with DCM. Two-dimensional echocardiography 
is a highly useful and readily available technique to assess ventricular 
size and performance and to exclude associated valvular or pericardial 
abnormalities. Doppler echocardiography permits the evaluation of 
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valvular regurgitation or stenosis and the quantification of cardiac output. 
Doppler detection of restrictive filling patterns may indicate disease of 
greater severity.  
Pericardial effusion may be present. Performing echocardiography 
during dobutamine stimulation may identify occult coronary artery 
disease by provoking regional wall motion abnormalities, differentiating 
these patients from those with idiopathic DCM. Moreover, significant 
contractile reserve during dobutamine infusion represents a positive 
prognostic finding. Three-dimensional echocardiography may be of 
additional value in assessing mitral valve orifice remodelling and 
determining ventricular dyssynchrony. 
Radionuclide Imaging 
Nuclear imaging protocols for myocardial perfusion stress imaging 
may be useful to exclude an ischemic cause of dilated heart failure. 
Radionuclide ventriculography also provides evidence of cardiac 
structure and function, showing increased chamber volumes at end 
diastole and end systole; it provides quantification of reduced ejection 
fraction in either or both ventricles, and it can elucidate the regional 
nature of wall motion abnormalities. Not always necessary, this technique 
can be of particular value if echocardiography is technically suboptimal. 
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Cardiac Magnetic Resonance Imaging and Multidetector Computed 
Tomography 
Cardiac magnetic resonance imaging (CMR) and multidetector 
computed tomography are relatively new imaging modalities that are 
likely to become increasingly useful to evaluate patients with 
cardiomyopathies49. Specific cardiomyopathic disorders in which CMR 
has proved particularly valuable include ARVD/C50, endocardial 
fibroelastosis, myocarditis51, amyloidosis52, and sarcoidosis. CMR 
evaluation is also emerging as a critical tool to understand DCM 
pathophysiology and may contribute to identification of patients at 
particular risk for complications, such as sudden cardiac death (e.g., 
within DCM subsets, those with or without areas of replacement fibrosis 
that may predispose to electrical instability and sudden cardiac death) 53. 
CMR is also emerging as an important tool in the delineation of 
infiltrative and inflammatory cardiomyopathies. 
Invasive Evaluation Including Endomyocardial Biopsy 
Catheterization for the exclusion of epicardial coronary disease is 
essential in the management of the patient presenting with DCM. Because 
DCM and heart failure increase the false-positive and false-negative rates 
of non-invasive nuclear assessment for myocardial ischemia, performance 
of coronary angiography is often necessary to exclude epicardial coronary 
obstructive disease20. It is increasingly relevant to obtain hemodynamic 
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assessments in individuals presenting with acute or worsening heart 
failure. Use of these diagnostic tests is currently nonuniform54. 
Catheterization usually reveals elevated left ventricular end-diastolic and 
pulmonary artery wedge pressures. Pulmonary arterial hypertension may 
be of variable degrees, ranging from mild to severe. The right ventricle is 
frequently involved and enlarged, hemodynamically manifesting with 
increased right ventricular end-diastolic, right atrial and central venous 
pressures. 
Left ventriculography demonstrates varying degrees of ventricular 
dilation and diffuse chamber hypo kinesis. There may be a degree of 
regionality to the decreased function resembling ischemic heart disease, 
although a diffuse pattern is frequently present. It is not always possible 
to distinguish between left ventricular dilation due to severe mitral 
regurgitation associated with primary mitral valve disease and DCM with 
secondary mitral regurgitation. 
Coronary arteriography is particularly important to exclude 
coronary obstructive disease. In patients with DCM, the arterial 
circulation is typically normal although vasodilator function may be 
abnormal. 
Biopsy 
The role of endomyocardial biopsy to evaluate the myocardium 
histologically has been historically controversial in the evaluation of the 
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patient presenting with structural heart disease or symptoms of heart 
failure55,56. Recently, however, expert guidelines have been published that 
offer significant guidance as to the indications for endomyocardial 
biopsy18. This procedure, which is routine in the management of heart 
transplant recipients, allows the acquisition of small pieces of 
myocardium by use of a flexible bioptome. Currently available bioptomes 
are advanced transvenously, most commonly by a right internal jugular 
venous approach, to the right ventricular septum. If it is required, the left 
ventricular septum may be sampled by a trans arterial approach. This 
procedure is currently performed with either fluoroscopic or 
echocardiographic guidance. Although not reported in the literature, the 
widespread use of disposable bioptomes, which have replaced reusable 
Stanford-Caves devices, has led to a reduction of complications, 
particularly right ventricle perforation. 
Perhaps the most compelling reason in favour of routine biopsy is 
the detection of a few relatively rare diseases in which accurate diagnosis 
yields a life-threatening disease with specific management21,51. For 
example, lymphocytic and giant cell myocarditis must be detected early 
in the course of the presentation for patients to survive and can be 
separated from each other only by histologic evaluation43,58. Biopsy is 
also an established method for grading the severity of anthracycline 
cardiomyopathy and has potential similar value for cardiac amyloidosis.  
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A biopsy finding that is negative for inflammation is also valuable 
in patients with rapidly progressive severe decompensated heart failure, 
insofar as it may prompt advancement to aggressive mechanical support 
earlier in the patient's clinical course. Whereas widespread use of the 
myocardial biopsy is no longer routinely recommended, recent guidelines 
and treatment trials continue to add clarity around appropriate selection of 
patients. In patients with fulminant heart failure, particularly those with 
new-onset cardiomyopathy, the risk-benefit assessment is more clearly in 
favour of performing a biopsy to more rationally allocate patients for 
emergent heart transplantation listing or for insertion of a mechanical 
assist device.  
Patients who have fulminant lymphocytic myocarditis have 
excellent long-term prognosis after short-term hemodynamic support21; 
those with giant cell myocarditis should be aggressively 
immunosuppressed or listed for heart transplantation58; and those with 
idiopathic cardiomyopathy (suggested by the absence of myocardial 
inflammation on biopsy) should be aggressively supported and converted 
to conventional therapy once stabilized.  
Management 
Pharmacologic and Device Therapy 
Whereas the concept of specific etiology-based therapies represents 
an ongoing quest for patients with DCM, the general treatment of these 
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patients should follow the practice guidelines for all patients with heart 
failure59. Similarly, the use of prophylactic implantable cardiac 
defibrillators and biventricular pacemakers is indicated in appropriate 
patients with nonischemic and ischemic DCM 59,60. 
Surgery 
Patients with valvular heart disease, coronary artery disease, 
pericardial disease, or congenital heart defects should have these 
conditions corrected surgically, when appropriate. Other specific 
operations geared toward the cardiomyopathic heart include approaches 
motivated by the concept of restoring chamber geometry or interventions 
to provide mechanical support. Approaches to achievement of reverse 
remodelling surgically include left ventricular reconstruction and 
implantation of external restraint devices. Left ventricular assist devices 
provide aggressive mechanical support to patients with advanced 
decompensated heart failure.  
Emerging Specific Therapies 
Only recently are specific etiology-based therapies being 
evaluated. These include agents to eradicate persistent viral infections and 
immunomodulatory agents. Stem cells for cardiac regeneration and gene 
therapy approaches are in clinical trials. 
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MATERIALS AND METHODS 
Place Of Study : Institute of internal medicine, RGGGH, MMC. 
Study Design : Cross sectional study 
Ethical Committee Clearance : Obtained 
Period of Study:  May 2011 to Oct 2011 
SELECTION CRITERIA 
Inclusion Criteria 
1. Clinical criteria: 
Patients with symptoms and signs of heart failure. 
2. ECHO criteria: 
Left ventricular ejection fraction < 45% 
Global hyokinesiaof LV 
Dilatation of all the chambers of heart 
Left ventricular end diastolic dimension > 3 cm / body surface 
area. 
Exclusion criteria 
1. Pericardial disease 
2. Corpulmonale with CHF. 
3. Hypertrophic cardiomyopathy 
4. Restrictive cardiomyopathy 
5. Congenital heart disease 
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STUDY POPULATION 
The subjects for the study were selected from cases admitted to the 
medical wards of Government General Hospital, Chennai during the 
period from May 2011 to Oct 2011 who fitted in the criteria described 
above. The diagnosis of dilated cardiomyopathy was made on the basis of 
history, physical findings and echocardiographic features. 
 
STUDY DESIGN: Cross sectional study 
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METHODOLOGY 
100 representative cases of dilated cardiomyopathy which fitted in 
the criteria were selected. A detailed history was obtained from them and 
symptom analysis was done. A detailed clinical examination was also 
done. 
A 12 lead electrocardiogram was obtained and analysed. 
A chest radiograph which comprised of a posteroanterior chest film 
was obtained. In all cases the cardio thoracic ratio, pulmonary infiltrates, 
pulmonary plethora, pleural effusion was looked for. 
Echocardiogram was done for all patients. In all patients chamber 
dimension, EF, global hypokinesia were looked for and the results are 
interpreted. 
The diagnosis of ischemic DCM was based on either past history of 
myocardial infarction or coronary angiography demonstrates significant 
luminal occlusion (>70%). 
Peripartum cardiomyopathy was diagnosed by using criteria laid 
down by Demakis et al which includes (1) Development of heart failure 
in the last month of pregnancy or within 5 months of delivery (2) absence 
of identifiable heart disease prior to the last month of pregnancy. (3) 
Echocardiogram demonstrates classical left ventricular dysfunction (4) 
Absence of other identifiable causes of heart failure. 
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The diagnosis of diabetic cardiomyopathy was made in patients 
with long standing (>10 years) diabetes mellitus and in whom no other 
cause was obvious. 
Similarly patients with echocardiography proven dilated 
cardiomyopathy with history oflong term (> 10 years) alcohol 
consumption in whom no other causes were found were diagnosed as 
alcoholic cardiomyopathy. 
If no obvious cause was found they are categorized as idiopathic 
DCM. 
The clinical profile along with the probable etiology, radiological and 
electrocardiographic findings were summarised and compared with 
existing data. 
COMPETING INTEREST: NIL 
FINANCIAL SUPPORT: NIL 
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TABLE 3: ALCOHOL DURATION 
 
 
PAST HISTORY OF MYOCARDIAL INFARCTION 
Past history of myocardial infarction present in 48 among 100 
patients. Among them documented ECG & ECHO records were available 
with thirty four of them. Only twenty one of them are under regular 
treatment. Eighteen of them are alcoholic & twenty four of them are 
smoker. 
SYMPTOMATOLOGY 
All the patients in this study presented with exertional dyspnea. 
Easy fatigability was observed in 83 % of subjects constituting the next 
most common symptom followed by pedal edema in 70 % of patients. 
History of paroxysmal nocturnal dyspnea,cough and palpitation were 
seen in 60 % of subjects followed by orthopnea 53 %, chest pain 35 %, 
abdominal pain 33 % and syncope 17 %. 
The details about the symptoms are depicted in the table 
 
Alcohol duration No. of cases Percentage 
< 10 Yrs 21 21 
10-20 Yrs 9 9 
>20 Yrs 6 6 
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PHYSICAL FINDINGS 
Basal crackles were seen in about 93 % of the subjects. Pedal 
edema wasseen in 77 %. Raised JVP was present in 73.3% and 
hepatomegaly in 47 %. Apicalpan systolic murmur was noticed in 47 % 
with LVS3 seen in 47 %. Pan systolic murmurin tricuspid area (TR) was 
present in 10% while RVS3 was present in 20% of our patients.Systolic 
blood pressure < 100 mmHg was observed in 31 % and four patients had 
stroke. 
 
TABLE 5: PHYSICAL FINDINGS 
Signs No. of cases Percentage 
Basal crackles 93 93 
Raised JVP 73 73 
Hepatomegaly 47 47 
Pedal edema 77 77 
LVS3 47 47 
RVS3 20 20 
PSM(MR) 47 47 
PSM(TR) 10 10 
SBP<100 mmHg 31 31 
Focal neurological 
deficit 
4 4 
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ELECTROCARDIOGRAM 
The electocardiographic profile includes abnormalities of rate, 
rhythm, axis and chamber enlargement. The most common abnormality 
noticed was ventricular ectopics seen in 46 % of patients. Sinus 
tachycardia was seen in 34 % of subjects. Left bundle branch block was 
seen in 42 % of patients. Right bundle branch block was seen in 13 %. 
Non specific ST-T changes were noticed in 29 % whereas AF was present 
in 14 %. Left ventricular hypertrophy was seen in 22 % and LAE in 16 % 
of subjects. Complete heart block was present in only 3 patient (3 %). 
The axis was almost normal in majority of patients. Left axis deviation 
was observed in 16 % and right axis deviation in 6 %. 
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TABLE 8: ECG CHANGES 
 
ECHOCARDIOGRAPHY 
The mean left ventricular ejection fraction was found to be 30.87 
%. The LV ejection fraction was less than 20% in 6% of patients. It was 
between 20-29% in 40 %, between 30-39% in 37 % of patients and 
between 40 to 45% in 17 % of patients. The mean LVEDD was 6.04 ± 
0.74 cm with majority i.e. 54 % ofsubjects having LV end diastolic 
diameter more than 6 cm. The mean LVESD was 4.92 ± 0.62cm; with 
majority of patients (47 %) having end systolic diameter more than 5 cm. 
Global hypokinesia and dilatation of all 4 chambers were seen in 
Parameters  n % 
QRS Axis 
Normal 74 74 
Left axis deviation 17 17 
Right axis deviation 9 9 
Arrhythmias 
Sinus tachycardia 45 45 
Atrial ectopics 11 11 
AF 14 14 
SVT 7 7 
Ventricular ectopics 46 46 
VT 4 4 
CHB 3 3 
LBBB 42 42 
RBBB 13 13 
ST-T Changes  29 29 
Atrial enlargement 
LAE 16 16 
RAE 6 6 
Ventricular hypertrophy 
LVH 22 22 
RVH 9 9 
BOTH 6 6 
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almostall the patients. In our study 68 % of patients had mitral 
regurgitation, 8 % of patients had tricuspid regurgitation and 9 % of 
patients had pericardial effusion. 
TABLE 9: ECHO CHANGES 
Parameter Range No. of cases % 
EF 
40-45% 17 17 
30-39% 37 37 
20-29% 40 40 
<20% 6 6 
LVEDD 
4.5-4.9cm 13 13 
5.0-5.9cm 33 33 
>6cm 54 54 
LVSD 
3.5-4cm 20 20 
4-4.9cm 33 33 
>5cm 47 47 
MR  68 68 
TR  8 8 
AR  4 4 
Pericardial effusion  9 9 
 
 
 
 
 
 NYHA C
Majority 
class IV (
C
C
C
C
 
HEART 
Biv
LV failure
 
 
LASS 
of the pat
47%) grou
NYHA 
lass 1 
lass 11 
lass 111 
lass 1V 
FIGUR
FAILUR
entricular
 was seen
0
10
20
30
40
50
C
PE
R
C
EN
TA
G
E
ients in o
p. 
TABL
Class 
E 6: GRA
E 
 failure w
 in19 %. 
lass 1 Clas
3
55
ur study w
E 10: NY
No. of
3
1
3
4
PH SHO
as presen
4 % of pa
s 11 Class 1
17
33
NYHA C
ere in N
HA CLA
 cases 
 
7 
3 
7 
WING N
t in 77 %
tients in o
11 Class 1V
47
lass
YHA cla
SS 
Perc
YHA CL
 of patie
ur study h
ss III (33%
entage 
3 
17 
33 
47 
ASS 
nts and i
ad RV fa
NYHA Class
) and 
 
solated 
ilure. 
 L
R
B
 
F
CAUSES
The
ischemic 
cardiomy
diabetic c
subjects 
Miscellan
ofvalvular
Heart f
VF 
VF 
iventricu
IGURE 7
 OF DILA
 most com
dilated c
opathies 
ardiomyo
while p
eous grou
 cardi
0
20
40
60
80
PE
R
C
EN
TA
G
E
TABLE 
ailure 
lar 
 : GRAP
TED CA
mon typ
ardiomyop
followed 
pathy (11
eripartum
p include
omyopath
LVF
19
56
11: HEA
No. o
7
H SHOW
RDIOM
e of dilate
athy in 
by alcoh
 %).Idiop
 cardiom
d 6 cases
y (mit
RVF
4
Failu
RT FAIL
f cases 
19 
4 
7 
ING HE
YOPATH
d cardiom
our study
olic card
athic DC
yopathy
 (6 %),w
ral reg
Biventricu
77
re
URE 
Per
ART FA
Y 
yopathy 
 comprisi
iomyopat
M was s
 was s
hich inclu
urgitation
lar
centage 
19 
4 
77 
ILURE 
was foun
ng 47 %
hy (15 %
een in 12
een in 
des three
 & 
Failure
 
d to be 
 of all 
) and 
 % of 
9 %. 
 cases 
aortic 
57 
 
regurgitation),two cases of HIV cardiomyopathy and one post viral 
myocarditis. 
TABLE 12: CAUSES OF DILATED CARDIOMYOPATHY 
Cause No.of Cases Percentage 
Ischemic 47 47 
Alcoholic 15 15 
Idiopathic 12 12 
Diabetic 11 11 
Peripartum 9 9 
Miscellaneous 6 6 
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TABLE 13: ALCOHOL INTAKE AND DCM 
 
FIGURE 10: GRAPH SHOWING ALCOHOL AND DCM 
 
ALCOHOL AND DCM
ALCOHOL  DOSE
P VALUE = <0.0001
D
C
M
>100g/day <100g/day
0
5
10
15
20
25
ALCOHOLIC DCM
NON ALCOHOLIC DCM
 
Alcohol intake Alcoholic DCM 
Non alcoholic 
DCM Total 
Present 15 21 36 
Absent 0 64 64 
Total 15 85 100 
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TABLE 14: COMPARISON OF EF & LVEDD AMONG 
ISCHEMIC AND NONISCHEMIC DCM 
 
Parameter All Cases Ischemic DCM 
Non Ischemic 
DCM P value 
Mean EF 31.26 ±7.59 31.10±8.44 31.40±6.83 0.85 
Mean LVEDD 6.044±0.75 6.07±0.79 6.02±0.71 0.72 
 
P value calculated using Fisher exact test. 
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DISCUSSION 
Among 100 patients in our study 57% were found to be males and 
the remainder were females. In males, dilated cardiomyopathy was most 
commonly seen in the elderly males (mean age 56.6±12.5 years).In 
females DCM was predominantly seen in middle age. The underlying 
etiology varied with the age group. In one study the mean age was 52.9 ± 
15.1 years in males and 51.3.9±17.7 years in females. In another study 
the mean age was 64.4 years in males and 55.5 years in females. In a 
study done in 2004, the mean age of presentation was found to be 
42.6±9.1 years, with males comprising 73.6% and females comprising 
26.4% of the study population. 
Symptomatology 
The most common presentation in our study was found to be 
biventricular failure which was seen in 77 % of cases. Isolated left 
ventricular failure was seen in 19 % of patients, most of them were 
ischemic DCM. Predominant right ventricular failure was seen in two 
patients with alcohol cardiomyopathy. Most of the patients were in 
NYHA class IV (47 %) and class III (33 %) while 17 % were in NYHA 
class II.  Dyspnoea was the commonest symptom found in almost all the 
patients. Paroxysmal nocturnal dyspnoea was seen in 60 patients (60%) 
while orthopnoea was noticed in 53 patients (53 %). 
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Cough  
Cough was present in 60% of our patients probably due to 
pulmonary congestion. Six patients (i.e. 6 %) in our study had respiratory 
infection like acute bronchitis and bronchopneumonia. 
Easy fatigability 
Easy fatigability was the second most commonest symptom found 
in 83 % of our subjects. It was noticed more commonly in patients with 
biventricular failure and less commonly in patients with isolated left 
ventricular failure. Easy fatigability was attributed mainly to chronic 
heart failure itself in most cases. In addition factors like anaemia, cardiac 
cachexia, etc. contribute to easy fatigability. 
Pedal edema 
Pedal edema was seen in majority (70%) of our patients. Pedal 
edema was the predominant symptom in patients with Alcoholic 
cardiomyopathy and idiopathic DCM. Anasarca was noticed in 11 
patients (i.e. 11 %) of which 5 had alcoholic DCM, 5 had ischemic DCM, 
while 1 had idiopathic DCM. 
Abdominal pain 
33% of patients in our study had abdominal pain. Abdominal pain 
was attributed to hepatic congestion. The other possible mechanism for 
abdominal pain in these patients could be gastritis. 
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Palpitation 
Palpitation was noticed in 60 patients (i.e. 60 %) in our study. 
Sinus tachycardia was seen in 57 % of patients secondary to chronic heart 
failure. Palpitation was also attributed due to atrial fibrillation, atrial / 
ventricular ectopics, and supra ventricular tachycardia etc. 
Chest pain  
In 35 % of our patients chest pain was present. Most of these 
patients had ischemic DCM. The cause of chest pain in these patients was 
found to be due to chronic myocardial ischemia.  
Syncope  
Syncope was present in 17 % of our patients. Syncope is mainly 
secondary to low cardiac output in most of the cases. 
 
 
Symptomatology Our study (%) Ahmad et al (%)60
Jain et al 
(%)61
Dyspnoea 100 96.3 100 
Easy fatigability 83 83.6 80 
Pedal edema 70 56 100 
PND 60 36.3 53 
Cough 60 56.3 52 
Palpitation 60 65.4 66.7 
Orthopnoea 53 40 100 
Abdominal pain 33 41.8 30 
Syncope 17 1.8 2 
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Physical signs 
Peripheral pulse 
Tachycardia was present in 45 % of patients. Bradycardia was 
present in 6 patients secondary to complete heart block. Atrial fibrillation 
was noticed in 14 % of patients. Ectopic beats was present in 23 % of 
patients in our study. Pulsus alternans was seen in three patients.  
Signs of left heart failure 
Basal crackles were present in 93 % of our patients in our study. 
Basal crackles were attributed mainly to pulmonary edema / pulmonary 
congestion secondary to LV failure. 
Cardiac examination revealed LVS3 in 47 % of our patients in this 
study. Pan-systolic murmur secondary due to mitral regurgitation were 
seen in 47 % of our patients. RVS3 was found in 20% of patients while 
PSM in left parasternal area secondary to TR was seen in 10% of patients. 
Signs of right heart failure 
Raised JVP 
Raised JVP was seen in 73 patients (i.e. 73 %) in our study secondary to 
RV failure. 
Hepatomegaly 
Hepatomegaly was present in 47 % of patients in our study secondary to 
congestive heart failure. 
Pedal edema was seen in 77 % of our patient in our study. 
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Others 
Four patients with ischemic dilated cardiomyopathy and AF had 
stroke which was secondary to cerebral embolism. Majority of the 
patients presented with biventricular failure.  
Exertional dyspnea was found to be the most common symptom in 
our study being present in all our patients followed by symptoms like 
easy fatigability, pedal edema, cough, palpitation and abdominal pain. 
This presentation is similar to the clinical profile seen in many other 
studies. 
In our study up to 35 % of patients had chest pain. This was high 
compared to other studies like S. Ahmad et alwhere in chest pain was 
seen in 29%. This could be due to inclusion of patients with ischemic 
cardiomyopathy as compared to the other study where it was excluded. 
In addition syncope was present in up to 17 % of our patients in this 
study, whereas in other studies syncope was seen only in 1.8% (S. Ahmed 
et al) 60.This high number could again be attributed due to the inclusion of 
ischemic cardiomyopathy in our study. Arrhythmias and severe left 
ventricular dysfunction are more commonly present in ischemic 
cardiomyopathy may lead to syncope.  
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Physical findings Our Study (%) S. Ahmad et al (%)60 
Basal crepitations 93 90 
Pedal edema 77 67.2 
Raised JVP 73 83 
Hepatomegaly 47 54 
LVS3 47 45 
RVS3 20 - 
 
Radiological features 
Chest radiograph was found to be abnormal in almost all the cases 
showing varying degree of cardiomegaly with CT ratio varying between 
0.5 to 0.75. This was similar to the study done by Masssumi et al, in that 
cardiomegaly was found in all cases with CT ratio between 0.51 to 0.80.  
27 % of patients in our study had pleural effusion compared to 46% in the 
Massumi et al study and 10% in Ahmad et al study.  
Pulmonary plethora was found in 51% as compared to 72% in Massumi 
et al study and 76.3% in the Ahmad et al study. 
Parameter Present study (%) 
Massumi et 
al(%)62 
Ahmad et 
al(%)60 
Cardiomegaly 100 100 96.3 
Pleural effusion 27 46 10 
Pulmonary 
plethora 51 72 76.2 
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Electrocardiographic profile 
The QRS axis was normal in 74 % of our subjects with left axis 
deviation in 17 % and right axis deviation in 9% which were in 
concordance with all the other studies. Sinus tachycardia was the most 
predominant finding in the S. Ahmad et al study being found in up to 
69% of patients. Our study showed sinus tachycardia in 45 % of patients.  
Other ECG parameters like ventricular ectopics, LBBB, Atrial 
fibrillation, atrial ectopics were comparable to those in all the other 
studies. However RBBB, complete heart block and SVT were more 
commonly present in our study as compared to other studies. These could 
again be due to the inclusion of ischemic cardiomyopathy in our study. 
LVH was less commonly seen in our study being present in 22 % as 
compared to 30 to 40% in other studies. 
Non specific ST-T changes were seen in 29% of cases in our study, 
similar to that in other studies. 
  
68 
 
Parameters  Our study S. Ahmad et al60
QRS axis Normal 74 70.9 
 LAD 17 20 
 RAD 9 9 
LVH  22 40 
ST-T changes  29 10 
Arrhythmias Ventricular ectopics 46 29.1 
 Sinus tachycardia 45 69.1 
 LBBB 42 32 
 RBBB 13 - 
 AF 14 9.1 
 Atrial ectopics 11 5.4 
 SVT 7 0 
 VT 4 0 
 CHB 3 10.9 
 
Echocardiographic profile 
The mean left ventricular EF in our study group was 30.34 %. This 
was similar to that in all the other studies on dilated cardiomyopathy.  
The mean LVEDD was 5.78 cm. The mean LVESD was 4.62 cm.  
Mitral regurgitation was seen in 68 % of our patients in our study 
comparable to that in other study groups. Mitral regurgitation (68 %) was 
much more commonly seen when compared to tricuspid regurgitation (8 
%). This was mainly due to large proportion of patients with ischemic 
DCM and severe LV dysfunction compared to nonischemicDCM. Six of 
our patients had AR in our study when compared to 17.8% of patients in 
Jain et al study. Mitral and tricuspid regurgitation in dilated 
cardiomyopathy are secondary to annular ring dilatation 
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Left ventricular clot was seen in four patients in our study who also had 
cerebral embolism secondary to atrial fibrillation. Pericardial effusion 
was seen in 9 % of our patients. 
Parameter
(mean) 
Our 
study 
Ahmad
et al 60 
Jain 
et al 61 
G. Singh 
et al 63 
Routray 
et al 64 
Rihal 
et al 65 
LV EF 30.34 30.05 29 30 35 23 
LV EDD 5.78 6.45 6.64 6.48 61 6.9 
LV ESD 4.62 5.8 5.74 5.63 52.3 6 
MR 68 63.6 67 90 86 43.13 
TR 8 26.3 46 48 36 24 
LV clot 4 3.6 4 6 11 6 
Pericardial 
effusion 9 4 10.44 12.4 5.5 8.2 
 
Etiological profile 
In our study the most common type of dilated cardiomyopathy was 
ischemic dilated cardiomyopathy being present in 47 % of our patients, 
followed by alcoholic cardiomyopathy seen in 15 %. Diabetic 
cardiomyopathy wasfound to be the third most common type seen in 11 
% of patients while Idiopathic and Peripartum cardiomyopathy were seen 
in 12 % and 9 % respectively. The miscellaneous group included 6 
patients; one with post viral myocarditis, two patients had HIV 
cardiomyopathy and three had valvular cardiomyopathy. Ischemic 
cardiomyopathy was not included in most studies on dilated 
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cardiomyopathy due to the controversy in defining the term “Ischemic 
cardiomyopathy”. 
In Jain et al study ischemic cardiomyopathy comprised 37% of 
cases followed by idiopathic dilated cardiomyopathy seen in 30% of 
patients. The incidence of idiopathic DCM in their study was much 
higher compared to our study. Other sub groups of DCM were 
comparable to our study. 
Coronary angiography was done in all the patients with ischemic 
cardiomyopathy in our study. Of the 47 patients studied 29 of them had 
history of previous myocardial infarction. All the 47 patients in our study 
had significant narrowing of epicardial coronaries (i.e. > 70% of lumen). 
Twenty one patients had double vessel disease, six showed triple vessel 
disease and two had single vessel disease. The echocardiography of all 
the patients showed global hypokinesia with reduced ejection fraction. 
Among the patients with alcoholic cardiomyopathy three had 
hepatic cirrhosis. Liver function tests revealed mildly raised bilirubin (1.5 
mg %) with normal liver enzymes. This is similar to that found in other 
studies on alcoholic cardiomyopathy. 
In our study 37 % of patients had anemia, most of the patients had 
mild anemia (i.e. Hb between 8.5 – 11 gm %). In a study done by A. 
Justin et al anemia was found in 27% of patients with congestive heart 
failure. The prevalence of anemia in our study is similar. Anemia is 
71 
 
known to be associated with adverse outcome in patients with heart 
failure. 
Etiology Our study (%) Jain et al (%) 61 
Ischemic 47 37 
Alcoholic 15 14.5 
Idiopathic 12 30 
Diabetic 11 7.8 
Peripartum 9 7 
Miscellaneous 6 3.7 
 
Among alcoholics alcohol plays a significant etiological role (p value 
<0.0001) 
The mean EF in our study was 31.2±7.5 
The mean LVEDD in our study was 6.04±0.74 
The mean LVESD in our study was 4.92±0.62 
There is no significant difference between EF & LVEDD among 
ischemic and non ischemic DCM (p value 0.85 and p value 0.72 
respectively) 
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SUMMARY 
¾ The objective of the study was to know the etiology and clinical 
profile including ECG and ECHO changes in dilated 
cardiomyopathy 100 cases of dilated cardiomyopathy, of which 57 
were males and 43 were female were included in the study. 
¾ Dilated cardiomyopathy is common in the elderly and middle aged 
population and the etiology varies with age. 
¾ Dilated cardiomyopathy is more common in males. 
¾ Biventricular failure was the most common clinical presentation 
(77 %) followed by left heart failure (19 %) and then right heart 
failure (4%). 
¾ The most common type was ischemic variety followed by 
alcoholic, idiopathic, diabetic and peripartum cardiomyopathy. 
¾ The electrocardiographic profile showed ventricular ectopics, sinus 
tachycardia, left bundle branch block, atrial fibrillation, right 
bundle branch block, atrial ectopics, SVT, ventricular tachycardia 
and complete heart block.LVH was present in 22 % of cases. 
¾ Chest radiography showed cardiomegaly in all the cases. 
Pulmonary plethora was noticed in significant number of patients 
(51 %). Pleural effusion was noticed in (27 %). 
¾ Echocardiographic profile included reduced EF and global 
hypokinesia in all the patients. There was also varying degree of 
73 
 
left ventricular dilatation. Mitral regurgitation was seen in 
significant number of patients (68 %). Pericardial effusion was 
seen in 9 % of the patients. 
¾ Most of the patients were in NYHA class IV (47 %) and class III 
(33%). 
¾ Among alcoholics alcohol plays a significant etiological role (p 
value <0.0001) 
¾ The mean EF in our study was 31.2±7.5 
¾ The mean LVEDD in our study was 6.04±0.74 
¾ The mean LVESD in our study was 4.92±0.62 
¾ There is no significant difference between EF & LVEDD among 
ischemic and non ischemic DCM (p value 0.85 and p value 0.72 
respectively) 
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CONCLUSION 
The major cause of dilated cardiomyopathy in our study was found 
to be ischemic followed by alcoholic and idiopathic cardiomyopathy. The 
most common clinical presentation is biventricular failure. Chest 
radiography showed cardiomegaly in most patients. The common 
abnormality in ECG consists of sinus tachycardia, AF, LBBB. ECHO 
showed reduced EF and global hypokinesia universally. Mitral 
regurgitation and pericardial effusion were present in significant number 
of patients. Most of the patients presented with NYHA class 1V.  
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KEY TO PROFORMA 
PND-Paroxysmal nocturnal dyspnoea             LVESD-Left ventricular end 
systolic dimension 
IHD- Ischemic heart disease                            LA-Left atrium 
MI-Myocardial infarction                                 RA-Right atrium 
DM-Diabetes mellitus                                       LV-Left ventricle 
SHT-Systemic hypertension                             RV-Right ventricle 
BP-Blood pressure  
JVP-Jugular venous pressure 
CNS-Central nervous system 
NYHA-Newyork heart association 
ECG-Electrocardiogram 
TC-Total count 
DC-Differential count 
ESR-Erythrocyte sedimentation rate 
RFT-Renal function test 
LFT-Liver function test 
CT Ratio-Cardio thoracic ratio 
EF-Ejection fraction 
LVEDD-Left ventricular end diastolic dimension 
  
KEY TO MASTER CHART 
DM-Diabetes mellitus 
SHT-Systemic hypertension 
IHD-Ischemic heart disease 
PND-Paroxysmal nocturnal dyspnoea 
JVP-Jugular venous pressure 
LVS3-Left ventricular S3 
RVS3-Right ventricular S3 
PSM-Pan systolic murmer 
NYHA-Newyork heart association 
EF-Ejection fraction 
LVEDD-Left ventricular end diastolic dimension 
LVESD-Left ventricular end systolic dimension 
B-Bradycardia 
ST-Sinus tachycardia 
AF-Atrial fibrillation 
VPC-Ventricular premature contraction 
CHB-Complete heart block 
 
  
PROFORMA 
 
Name:                                                       Age:                   Sex: 
Address: 
Unit/Ward: 
 
PRESENT HISTORY 
 
Breathlessness                                                   
Syncope 
Orthopnoea 
Palpitations 
PND                                                                   
Abdominal pain 
Chest pain                                                          
Pedal edema  
Cough 
 
PAST HISTORY 
 
IHD 
Diabetes mellitus 
Hypertension 
Alcohol 
HIV infection 
 
PERSONAL HISTORY 
 
Diet 
Smoking  
Alcohol 
Tobacco 
 
FAMILY HISTORY 
 
DM 
SHT 
Premature IHD(<40yrs) 
 
TREATMENT HISTORY 
 
 
 
GENERAL PHYSICAL EXAMINATION 
 
Weight 
Anaemia 
Jaundice 
Cyanosis 
Pedal edema 
Lymphadenopathy 
Pulse – Rate 
            Rhythm 
            Volume 
            Character 
            Other peripheral pulses: 
 
                                                                    Right                                           left 
 
                    Carotids 
                    Brachial 
                    Radial 
                    Femoral 
                    Popliteal 
                    Posterior tibial 
Dorsalispedis 
 
BP 
Respiratory rate 
JVP 
 
 
EXAMINATION OF CARDIOVASCULAR SYSTEM: 
 
INSPECTION – Apical impulse location 
                           Pulsation other than apical impulse 
Epigastric 
                           Lt parasternal 
                           Pulmonary area 
                           Suprasternal 
                           Supraclavicular 
 
PALPATION- Apical impulse- location/character 
 Lt para sternal heave 
Thrill 
  Palpable P2 
 Pulsations 
 
PERCUSSION- Rt border 
                           Lt border 
                           Lt 2nd space 
 
AUSCULTATION- Heart sounds S1,S2,S3 
Murmer – Site 
Character 
 Grade 
Radiation 
 
OTHER SYSTEMS 
 
RESPIRATORY SYSTEM 
ABDOMEN 
CNS 
 
DIAGNOSIS 
 
NYHA Class 
 
INVESTIGATIONS : 
 
COMPLETE HEMOGRAM 
 
Hb (g/dL) 
TC (cells/cmm) 
DC 
RBC(millions/cmm) 
Platelet(Lakhs/cmm) 
ESR 
 
RFT 
 
Blood Sugar(mg/dL) 
Blood Urea(mg/dL) 
S.Creatinine(mg/dL) 
S.Sodium(meq/l) 
S.Potasium(meq/l) 
 
LFT 
 
S.Bilirubin(mg/dL)  T: 
                                 D: 
Protein 
SGOT(IU/L) 
SGPT(IU/L) 
SAP(IU/L) 
 
Chest X ray – CT ratio 
                       Pulmonary vasculature 
                       Pleural effusion 
 
ECG-              Rate 
                        Rhythm 
                       Axis 
Pwave 
                       QRS 
Twave 
STsegment 
                       Conclusion 
 
ECHOCARDIOGRAM 
 
                              Measurement:                                                        Chambers: 
                                    EF         -                                                               LA- 
                                    LVEDD -                                   RA- 
                                    LVESD -                                                   LV-                              
           RV- 
 
                 Doppler study  –   Mitral valve 
                                             Tricuspid valve 
                                                    Aortic valve 
                                                   Pulmonary valve 
 
                             PE 
                             Thrombus/vegetation 
 
 
Others: 
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1 KANNAN 47 M  - +  +  3 + + + + + - + - - AF + + - + - - - 3 35 5.4 4.6 ISCHEMIC 
2 RAMASAMY 60 M +  +  +  4 - - + + + + + - + ST + + + - - + + 4 19 6.6 5.4 ISCHEMIC 
3 MURUGAN 61 M -  -  +  4 + + + - - - + - - ST + - - - - - + 4 21 6.8 5.6 ALCOHOLIC 
4 AMUDHA 36 F -  -  -  3 - - - - + - + - + AF - - + - + + - 3 36 6.4 5.5 PERIPARTUM 
5 RAVI 65 M  -  -  + 2 - - + - - - - - - ST + + - - - - - 2 40 6.5 5.2 ALCOHOLIC 
6 SHANTHI 19 F  -  -  - 4 + + - - + + + - + B + + + + - + + 4 23 6.9 5.5 IDIOPATHIC 
7 PONNUSAMY 51 M  +  -  - 4 - - - - - - + + + ST + - - - - + + 4 34 6.6 5.2 DIABETIC 
8 MANOHAR 72 M -  -  +  3 + + + - + - + - - ST + + + - - - - 3 23 5.4 4.5 ALCOHOLIC 
9 SAMPATH 66 M -  +  +  2 - - + + + + - - + VPC + + - - - + - 2 43 4.5 3.9 ISCHEMIC 
10 SIVASHANKAR 48 M  -  +  - 3 + + - + + - + + + ST + - + + - - - 3 37 5.4 4.2 ISCHEMIC 
11 ELANGO 61 M  -  -  + 4 + + + - + - + - + ST - + + + - + + 4 18 6.8 5.6 ALCOHOLIC 
12 SAROJA 41 F  +  +  - 4 + + - - - + + - - B + + - - - - - 4 23 6.4 5.5 ISCHEMIC 
13 MARIAMMAL 46 F  +  -  - 3 - - + - + + + - + ST + + + - + + - 3 35 5.4 4.9 DIABETIC 
14 DEVA 58 M  -  -  - 3 + - + - + - + - + VPC + + - + - + - 3 34 6.4 5.2 IDIOPATHIC 
15 KRISHNAMURTHY 72 M  -  +  + 4 - - + + + - + - - AF + - + - - - + 4 24 6.6 5.6 ISCHEMIC 
16 KUMARAN 68 M  -  +  + 2 - - - + - - - - + ST - - + - - + - 2 42 4.6 3.6 ISCHEMIC 
17 TAMIZHAN 67 M  -  +  + 2 + - + + + - + + + ST - - - + - + - 2 41 4.6 3.9 ISCHEMIC 
18 JEYANTHI 61 F  +  +  - 4 + + + + + + + - + ST + + - + - - + 4 25 6.8 5.5 ISCHEMIC 
19 THENMOZHI 62 F -   +  - 4 + + + + + - + - - AF + + - - - + + 4 18 6.4 5.3 ISCHEMIC 
20 SANTHANAM 66 M  -  -  - 3 + - + + + + + - + VPC + - + - + + - 3 34 5.4 4.6 IDIOPATHIC 
21 SUNDARAM 46 M  -  -  - 3 + + + - - - - - + ST + + + - + - - 3 43 5.4 4.9 HIV 
22 MANIGANDAN 65 M  -  +  + 4 + + + + - + - - + VPC - + - - + + + 4 26 6.9 5.5 ISCHEMIC 
23 GURUSAMY 52 M  -  -  + 3 + - + - + + + - - VPC + + + - - - - 3 38 5.3 4.6 ALCOHOLIC 
24 RANI 59 F  +  -  - 2 - - + - - - - + + ST + + + - + - + 2 42 4.5 3.5 DIABETIC 
25 MALAYAPPAN 64 M  -  +  - 2 - - + + + + + - - VPC + - + - + - - 2 44 4.5 3.6 ISCHEMIC 
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26 RAMANATHAN 51 M  +  +  - 4 + + + - + + + - + ST + + + - + - + 4 28 6.6 5.2 ISCHEMIC 
27 RANGANATHAN 60 M  +  -  - 4 + + - - + - + + + ST + - + - - - + 4 28 6.8 5.3 DIABETIC 
28 PORKODI 71 F  -  +  - 3 + - + + + - + - + VPC + + - + - + - 3 38 5.3 4.2 ISCHEMIC 
29 RAMALAKSHMI 51 F  +  +  - 3 - - - - + - + - - ST + + + + - + - 3 38 6.4 5.4 ISCHEMIC 
30 ELAVARASAN 56 M  -  -  + 4 + + + - + + + - + AF + - - + - - - 4 28 6.9 5.5 ALCOHOLIC 
31 PANDIYAN 63 M  -  -  - 3 - - - - - - + + + ST + + + - + - - 3 36 5.3 4.9 IDIOPATHIC 
32 GANDHIMATHI 38 F  -  -  - 4 + + + - + - + - + ST + - + + - + + 4 26 6.6 5.5 PERIPARTUM 
33 MALARKODI 56 F  -  +  - 3 - - - + - + + - - VPC + + + + - - - 3 21 6.8 5.3 ISCHEMIC 
34 SATHYAMURTI 60 M  -  +  - 2 - - + + + - - - + ST - - - - - - - 2 41 4.6 3.9 ISCHEMIC 
35 PUSHPARANI 47 F  -  -  - 2 - - - - + - - - + ST + + + - - + - 2 43 5.5 4.9 IDIOPATHIC 
36 KUPPUSAMY 44 M  -  -  - 4 + + - - - + + + + AF + - + + - - + 4 19 5.5 4.6 HIV 
37 PREMAKUMARI 69 F  -  +  - 4 + + + + + + + - - B + + + - - - - 4 23 6.7 5.6 ISCHEMIC 
38 KODANDARAMAN 36 M  +  +  - 3 - - + + - + + - + ST + + - + - + - 3 23 5.3 4.5 ISCHEMIC 
39 VIJAYALAKSHMI 67 F  -  +  - 3 - - + - + - + + + VPC + + + + - + - 3 23 6.9 5.6 ISCHEMIC 
40 PURUSHOTHAMAN 61 M -  -  - 2 - - + - - - + - - ST + + - + - - - 2 42 4.7 3.5 IDIOPATHIC 
41 GURUMURTI 55 M  -  -  + 3 - - + - + + + - - ST + + + - + - - 3 38 5.3 4.2 ALCOHOLIC 
42 SRINIVASAN 45 M  -  +  + 3 - - + - - - + - - ST + + - + - - - 3 36 5.5 4.6 ISCHEMIC 
43 VIJAYALAKSHMI 62 F  +  +  - 3 + + - + + - - + + AF + + - + - + - 3 38 5.5 4.9 ISCHEMIC 
44 VASANTHI 65 F  +  +  - 4 + + + + - + + - + ST + - + - + + + 4 24 6.6 5.4 ISCHEMIC 
45 RAMANATHAN 56 M  +  -  + 4 + + + + + - + - + VPC + + - + - - + 4 25 6.8 5.2 DIABETIC 
46 RAJAKUMARAN 35 M  -  -  + 4 + + - - - + + + - ST + + + + - + + 4 18 6.4 5.3 ALCOHOLIC 
47 MARIAMMAL 55 F  -  -  - 3 - - + - + + + - + ST + - - + - - - 3 38 5.5 4.2 IDIOPATHIC 
48 RAMAMURTHY 66 M  -  +  + 1 - - + + - - - - - VPC + + + - + + - 1 44 4.8 3.9 ISCHEMIC 
49 VENNILA 29 F - - - 3 + + - - + - + - + VPC + + - - - - - 3 38 5.5 4.6 PERIPARTUM 
50 VENUGOPAL 38 M  +  +  - 2 - - + - + - + - + ST + - + + - + - 2 41 6.9 5.5 ISCHEMIC 
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51 PRABHAKARAN 50 M  -  +  + 2 - - + + - + + - - ST + + - + - + - 2 40 5.5 4.5 ISCHEMIC 
52 PRABHAKARAN 61 M  -  +  - 4 + + - + + - + + + VPC + + + + - + + 4 26 6.6 5.2 ISCHEMIC 
53 ARIVALAGAN 51 M  +  -  + 1 - - + -- + - - - + ST + + - - - - - 1 42 4.9 3.6 ALCOHOLIC 
54 KOWSALYA 60 F  -  -  - 4 + + + - - + + - - VPC + + + - + - + 4 26 6.8 5.5 VALVULAR 
55 MADURAIVELAN 59 M  -  -  + 4 + + - - + - + - + VPC + + - + - - + 4 28 6.4 5.6 ALCOHOLIC 
56 NIRMALA 27 F  -  -  - 4 + + - - + - + - - VPC + + + - - - - 4 28 5.9 4.5 PERIPARTUM 
57 PANNERSELVAM 67 M  -  -  - 3 + + - - - + + - - ST + + + + - + - 3 38 5.5 4.9 IDIOPATHIC 
58 VIJAYALAKSHMI 62 F  +  +  - 4 + + - + + - + - + AF + - - + - + + 4 34 6.9 5.4 ISCHEMIC 
59 KRISHNAN 68 M  +  -  + 3 + - + - - - + + + ST + + + - + - - 3 38 5.7 4.5 DIABETIC 
60 RANIAMMAL 65 F  -  +  - 4 + + - + + - + - + ST + + - + - + + 4 26 6.6 5.2 ISCHEMIC 
61 KUMARAN 39 M  -  -  - 3 - - + - - + + - + VPC + - - + - - - 3 34 5.7 4.6 IDIOPATHIC 
62 PAVALAVENI 60 F  +  +  - 4 + + + + + - + - - AF + + + - - - + 4 21 6.8 5.2 ISCHEMIC 
63 MUTHUKUMARI 61 F  -  +  - 4 + + - + - - + + + ST + - + - + - + 4 19 6.4 5.3 ISCHEMIC 
64 GURUBARAN 69 M  -  -  + 3 - - + - + + + - + ST + + - - - + - 3 23 5.7 4.2 ALCOHOLIC 
65 MANIMEGALAI 72 F  -  +  - 3 + + - - + - + - - ST - + + + - + - 3 23 5.7 4.7 ISCHEMIC 
66 MANIKUMAR 70 M  +  -  - 2 - - + - - - - - + ST + - - + - - - 2 31 4.7 3.9 DIABETIC 
67 MURUGESAN 39 M  -  +  + 2 - - + - + + - - - ST + + + - + + - 2 43 6.7 5.5 ISCHEMIC 
68 MALATHY 56 F  -  -  - 2 - - + - - - + - + AF + + - - - - - 2 31 5.8 4.6 VALVULAR 
69 RAJADEVI 60 F  +  +  - 4 + + - + + - + - - ST + + + + - + + 4 24 6.6 5.3 ISCHEMIC 
70 MURUGANATHAN 71 M  -  +  + 4 + + - + - + + - + VPC + + - + - - - 4 25 6.8 5.2 ISCHEMIC 
71 RAMASUBBU 35 M  -  +  + 4 + + - - + + + - + ST + - + - + + + 4 26 6.4 5.4 ISCHEMIC 
72 KANDASAMY 63 M  -  -  + 2 - - + - - - + - + B + + + + - - - 2 38 4.8 3.5 ALCOHOLIC 
73 SUSEELA 36 F  -  -  - 3 + + - + + - - - - ST + + - + - + - 3 38 5.7 4.9 PERIPARTUM 
74 RAMARPILLAI 64 M  -  -  + 4 + + - - - - + - + ST + + + - + + + 4 28 6.9 5.6 ALCOHOLIC 
75 RUPAVATHI 59 F  -  -  - 3 - - + - + - + - + ST - - - + - - - 3 36 5.9 4.5 IDIOPATHIC 
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76 MUTHUSAMY 65 M  +  -  + 4 + + + - - + + - - VPC + + + - + + + 4 28 6.6 5.2 DIABETIC 
77 KAMALA 71 F  -  +  - 3 + - + - + - + + + ST + + - - - - - 3 38 6.8 5.4 ISCHEMIC 
78 SELVI 29 F  -  -  - 4 + + - - - - + + + ST + - - + - + - 4 27 6.4 5.2 PERIPARTUM 
79 THAMBIDURAI 66 M  -  +  + 2 - - + + + - - - + ST + + - + - + - 2 39 6.9 5.3 ISCHEMIC 
80 PADMAVATHY 70 F  +  +  - 3 - - + + + - + - - AF + + - + - - - 3 36 5.7 4.9 ISCHEMIC 
81 MADIALAGAN 67 M  -  +  + 4 + + + - + + + - + ST + + + - - + - 4 26 6.6 5.5 ISCHEMIC 
82 POORNIMA 34 F  -  -  - 2 - - + - - - + - + AF + + - + - + - 2 44 4.9 3.6 PERIPARTUM 
83 MURUGAN 68 M  -  +  + 3 - - + + + - + - - ST + - - - - - - 3 34 5.9 4.2 ISCHEMIC 
84 KALAISELVI 61 F  +  +  - 4 + + - - + - + - + VPC + + + + - + + 4 21 6.8 5.6 ISCHEMIC 
85 KUPPUSAMY 71 M  -  +  + 4 + + - - - + + - + ST + + - - - - - 4 23 5.8 4.9 ISCHEMIC 
86 PANDIDURAI 38 M  -  -  + 4 + + - - + - + - + ST + + - + - + + 4 23 6.4 5.3 ALCOHOLIC 
87 PUSHPAVATHY 58 F  -  -  - 1 - - + - + - - - + VPC + + + + - - - 1 38 4.9 3.9 IDIOPATHIC 
88 KANDASAMY 63 M  +  -  - 4 + + - - + + + - + ST + + - - - + - 4 24 5.8 4.5 DIABETIC 
89 AMBIKA 60 F  -  +  - 4 + + - - + - + - + AF + +  - - - - - 4 25 6.9 5.6 ISCHEMIC 
90 KAMALA 64 F  -  +  - 3 - - + + - - + - + ST + + - + - + - 3 36 5.8 4.9 ISCHEMIC 
91 KAMALAMMAL 62 F  +  +  - 4 + + - - + - + - + ST + + - + - + - 4 26 6.6 5.6 ISCHEMIC 
92 DHANDAPANI 65 M  -  -  + 4 + + + - - - + - + VPC + + - - - - - 4 38 6.8 5.6 ALCOHOLIC 
93 SURIYAPRIYA 55 F  -  -  - 4 + + - - - + + - + B + - - + - + - 4 28 6.9 5.5 IDIOPATHIC 
94 RAMANATHAN 66 M  +  -  - 3 - - + - + - + - - ST - + + - + - - 3 31 5.9 4.6 DIABETIC 
95 PRIYAKUMARI 51 F  -  -  - 4 + + - - - - + + + ST + + - - - + + 4 28 6.9 5.6 VALVULAR 
96 ASHOKKUMAR 18 M  -  -  - 4 + + - - - - + - + VPC + + - - - - - 4 28 6.6 5.5  POST VIRAL MYOCARDITIS 
97 BEEVIJOHN 36 F  -  -  - 4 + + + - + - + - + ST + - - + - - - 4 32 6.8 5.6 PERIPARTUM 
98 ELANKUMARAN 67 M  +  -  + 4 + + - - - - + - + B + + - - - - - 4 32 6.4 5.3 DIABETIC 
99 MARIAMMAL 38 F  -  -  - 3 - - + - - - - + + ST + + - - - - - 3 34 5.8 4.9 PERIPARTUM 
100 FATHIMA 60 F  -  +  - 4 + + - + - - + - + AF + + - -   - - 4 26 6.9 5.6 ISCHEMIC 
 
